查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600052

糖尿病药物市场：按产品、应用和分销管道 - 全球预测 2025-2030

Diabetes Drugs Market by Product (Insulin, Non-Insulin Injectable Drugs, Oral Drug), Application (Gestational Diabetes, Type 1 Diabetes, Type 2 Diabetes), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年糖尿病药物市场规模为691.2亿美元，预计2024年将达到729.7亿美元，复合年增长率为5.88%，预计到2030年将达到1031.8亿美元。

糖尿病药物市场包括旨在改善糖尿病患者血糖值的药物，包括第1型糖尿病、第2型糖尿病和妊娠糖尿病。由于久坐的生活方式、不健康的饮食和人口老化等因素，全球糖尿病盛行率不断上升，这个市场变得越来越重要。抗糖尿病药物的核心和最终用途范围包括血糖值管理，以降低急性和长期併发症的风险并改善患者的生活品质。根据市场洞察，关键的成长要素包括药物配方的持续进步、糖尿病管理意识的提高以及对医疗基础设施的大量投资。此外，新兴国家糖尿病盛行率的不断上升也为市场扩张提供了潜在的机会。最新的商机可以在提供个人化医疗和全面糖尿病管理解决方案的数位工具的开发中找到。然而，阻碍市场成长的挑战包括严格的法律规范、与糖尿病药物相关的副作用以及可能限制低收入地区获得的先进治疗的高成本。潜在的创新领域包括增强智慧胰岛素笔等药物传递系统，以及将人工智慧融入糖尿病管理以改善治疗结果。此外，SGLT2 抑制剂和 GLP-1 受体促效剂等新型治疗药物的开发持续塑造市场格局。另外值得注意的是，製药公司和高科技公司之间的合作可以促进创造更具创新性的综合解决方案。简而言之，在技术进步以及对更有效率、更容易获得的糖尿病治疗解决方案日益增长的需求的推动下，市场充满活力且充满潜力。然而，抓住这些机会需要克服监管和成本障碍，凸显了研发策略投资对推动业务成长的重要性。

主要市场统计
基准年[2023] 691.2亿美元
预测年份 [2024] 729.7亿美元
预测年份 [2030] 1031.8亿美元
复合年增长率（%） 5.88%

市场动态：揭示快速发展的糖尿病药物市场的关键市场洞察

供需的动态交互作用正在改变糖尿病药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球糖尿病盛行率不断上升
    • 政府针对糖尿病的措施和支持性卫生政策
    • 活性化先进配方的研发
  • 市场限制因素
    • 糖尿病药物高成本，糖尿病管理复杂
  • 市场机会
    • 建立实验室与製药公司之间的合作关係
    • 消费者对个人化医疗的需求不断增长
  • 市场挑战
    • 严格的政府核准流程

波特五力：驾驭糖尿病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解糖尿病药物市场的外部影响

外部宏观环境因素在塑造糖尿病药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解糖尿病治疗市场的竞争状况

糖尿病药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵式糖尿病药物市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘糖尿病治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，糖尿病治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球糖尿病盛行率正在上升
      • 政府针对糖尿病的措施和支持性卫生政策
      • 扩大先进药物配方的研发活动
    • 抑制因素
      • 糖尿病药物高成本，糖尿病管理复杂
    • 机会
      • 研究实验室与製药公司之间的新合作
      • 消费者对个人化医疗的需求增加
    • 任务
      • 严格的政府核准流程
  • 市场区隔分析
    • 产品：消费者对长效胰岛素药物的需求不断增加
    • 应用：越来越多用于治疗第2型糖尿病
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章糖尿病药物市场：副产品

  • 胰岛素
    • 中效胰岛素
    • 长效胰岛素
    • 混合胰岛素
    • 速效胰岛素
    • 速效胰岛素
  • 除胰岛素外的注射药物
    • Amylin 类似物
    • GLP-1受体促效剂
  • 口服药物
    • 双胍
    • DPP-4抑制剂
    • SGLT-2抑制剂
    • 磺酰尿素类
    • 胰岛素增敏剂

第七章糖尿病药物市场：依应用分类

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第八章糖尿病药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美糖尿病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区糖尿病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲糖尿病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 礼来公司糖尿病治疗药物替泽帕肽在中国获得核准
    • 赛诺菲印度公司推出了 Soliqua，一种治疗 2 型糖尿病和肥胖症的药物，旨在简化治疗并提高依从性。
    • Lupin 获得美国FDA核准非专利药糖尿病药物，目标是透过具有竞争力的定价和策略性扩张，实现每年 500 万美元的美国市场
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries（Julphar）
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA051C3

The Diabetes Drugs Market was valued at USD 69.12 billion in 2023, expected to reach USD 72.97 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 103.18 billion by 2030.

The diabetes drugs market encompasses pharmaceuticals aiming to improve blood sugar levels in individuals with diabetes, including type 1, type 2, and gestational diabetes. This market has become increasingly crucial as the prevalence of diabetes globally is rising due to factors like sedentary lifestyles, unhealthy diets, and aging populations. The core applications and end-use scope of diabetes drugs involve managing blood glucose levels to mitigate the risk of acute and long-term complications, improving the quality of life for patients. Market insights reveal that key growth influencers include the continuous advancements in drug formulation, increasing awareness about diabetes management, and substantial investments in healthcare infrastructure. Moreover, the increasing incidence of diabetes in emerging economies presents potential opportunities for market expansion. Latest opportunities can be found in the development of personalized medicine and digital tools that offer comprehensive diabetes management solutions. However, limitations challenging market growth include stringent regulatory frameworks, side effects associated with diabetes medication, and the high cost of advanced therapeutic drugs, which may limit access in low-income regions. Areas poised for innovation include enhancing drug delivery systems, such as smart insulin pens, and the integration of artificial intelligence in diabetes management to enhance therapeutic outcomes. Furthermore, the development of novel therapeutic classes, including SGLT2 inhibitors and GLP-1 receptor agonists, continues to shape the market landscape. It's also noteworthy that collaboration between pharmaceutical companies and tech firms could facilitate the creation of more innovative, integrated solutions. In essence, the market is dynamic and ripe with potential, driven by technological advances and a growing need for more efficacious and accessible diabetic care solutions. However, capturing these opportunities necessitates overcoming regulatory and cost barriers, emphasizing the importance of strategic investment in research and development to propel business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 69.12 billion
Estimated Year [2024] USD 72.97 billion
Forecast Year [2030] USD 103.18 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetes Drugs Market

The Diabetes Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes globally
    • Government Initiatives and supportive health policies for diabetes
    • Growing research and development activities for advanced drug formulations
  • Market Restraints
    • High cost of diabetes medications and complexity of diabetes management
  • Market Opportunities
    • Emerging collaborations among research labs and pharmaceutical companies
    • Rising demand for personalized medicine among consumers
  • Market Challenges
    • Stringent government approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Diabetes Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetes Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetes Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetes Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetes Drugs Market

A detailed market share analysis in the Diabetes Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetes Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetes Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetes Drugs Market

A strategic analysis of the Diabetes Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Biocon Limited, Bioton S.A., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Eva Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Gulf Pharmaceutical Industries (Julphar), Johnson & Johnson Services, Inc., Lupin Limited, MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Insulin, Non-Insulin Injectable Drugs, and Oral Drug. The Insulin is further studied across Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin, Rapid-Acting Insulin, and Short-Acting Insulin. The Non-Insulin Injectable Drugs is further studied across Amylin Analogs and GLP-1 Receptor Agonists. The Oral Drug is further studied across Biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, Sulfonylureas, and Thiazolidinediones.
  • Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes globally
      • 5.1.1.2. Government Initiatives and supportive health policies for diabetes
      • 5.1.1.3. Growing research and development activities for advanced drug formulations
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diabetes medications and complexity of diabetes management
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging collaborations among research labs and pharmaceutical companies
      • 5.1.3.2. Rising demand for personalized medicine among consumers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government approval procedures
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for long-acting insulin drugs among consumers
    • 5.2.2. Application: Increasing application for treatment of type 2 diabetes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetes Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Insulin
    • 6.2.1. Intermediate-Acting Insulin
    • 6.2.2. Long-Acting Insulin
    • 6.2.3. Premixed Insulin
    • 6.2.4. Rapid-Acting Insulin
    • 6.2.5. Short-Acting Insulin
  • 6.3. Non-Insulin Injectable Drugs
    • 6.3.1. Amylin Analogs
    • 6.3.2. GLP-1 Receptor Agonists
  • 6.4. Oral Drug
    • 6.4.1. Biguanides
    • 6.4.2. DPP-4 inhibitors
    • 6.4.3. SGLT-2 inhibitors
    • 6.4.4. Sulfonylureas
    • 6.4.5. Thiazolidinediones

7. Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Gestational Diabetes
  • 7.3. Type 1 Diabetes
  • 7.4. Type 2 Diabetes

8. Diabetes Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Eli Lilly gains approval for diabetes drug Tirzepatide in China
    • 12.3.2. Sanofi India launches Soliqua for Type 2 diabetes and obesity, aiming to simplify treatment and improve compliance
    • 12.3.3. Lupin secures USFDA approval for a generic diabetes drug, targets USD 5 million annual US market with competitive pricing and strategic expansion
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Baxter International, Inc.
  • 5. Bayer AG
  • 6. Biocon Limited
  • 7. Bioton S.A.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Eva Pharma
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Limited
  • 14. Gulf Pharmaceutical Industries (Julphar)
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lupin Limited
  • 17. MannKind Corporation
  • 18. Merck & Co., Inc.
  • 19. MJ Biopharm Pvt. Ltd.
  • 20. Novartis AG
  • 21. Novo Nordisk A/S
  • 22. Oramed Pharmaceuticals Inc.
  • 23. Pfizer Inc.
  • 24. Sanofi S.A.
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 27. Viatris Inc.
  • 28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETES DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETES DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023